OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Crane on Combinations With PARP Inhibitors in Ovarian Cancer

February 17th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses combinations with PARP inhibitors in ovarian cancer.

Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

February 17th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPC

February 17th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

February 17th 2018

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Dr. Stinchcombe on the KEYNOTE-189 Trial in Lung Cancer

February 17th 2018

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

Dr. Arend on Novel Combination Strategies in Gynecologic Cancer

February 17th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses novel combination strategies in gynecologic cancer.

Dr. Bardia on the Role of the Microenvironment in TNBC

February 17th 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the role of the microenvironment in the treatment of metastatic triple-negative breast cancer (TNBC).

Dr. Lagunes on the Importance of Developing More Personalized Treatments in NETs

February 16th 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the necessity of tailored approaches in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Perl Discusses the Impact of CAR T-Cell Therapy on ALL

February 16th 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Sonpavde on Immunotherapy Combination Studies in Urothelial Carcinoma

February 16th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy combination studies for the treatment of patients with urothelial carcinoma.

Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer

February 16th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

Dr. Wysock on the Role of Cytoreductive Nephrectomy in RCC

February 15th 2018

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma.

Dr. Francis on Ovarian Suppression in Young Women With Breast Cancer

February 15th 2018

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses ovarian suppression in young women with hormone receptor (HR)-positive breast cancer.

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

February 15th 2018

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Dr. Kudo Discusses TACE Plus Sorafenib in HCC

February 15th 2018

Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).

Dr. Marshall on Single-Agent and Combination Immunotherapy Applications in MSI-H mCRC

February 15th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the progression of immunotherapy in colon cancer.

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

February 14th 2018

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

Dr. Locke Discusses the Impact of the ZUMA-1 Trial in NHL

February 14th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses the impact of the ZUMA-1 trial for patients with non-Hodgkin Lymphoma (NHL).

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

February 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

Dr. Hill Discusses BTK Inhibitors in Mantle Cell Lymphoma

February 14th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses BTK inhibitors in mantle cell lymphoma (MCL).